Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the closing of its initial public offering of 27,600,000 units, including 3,600,000 units pursuant to the ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Collaborative research defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation. The method, ...

ABSTRACT: Systematic effort dedicated to the exploration of feasible ways how to permanently come up with even more space-efficient implementation of digital circuits based on conventional CMOS ...

Researchers have developed a new technology that improves the precision and integration density of synthetic genetic circuits. Professor Jongmin Kim's research team at POSTECH developed a new ...

The research team led by Professor Jongmin Kim from the Department of Life Sciences at POSTECH, along with graduate students Hyunseop Goh and Seungdo Choi, has successfully developed the 'Synthetic ...

Abstract: In this contribution, we explore Cartesian Genetic Programming for image analysis of biomedical data. Producing large quantities of human-labeled biomedical data is an expensive task. Here, ...